source
- FDA greenlights first oral therapy for adult dermatomyositisThe U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as a treatment for adults with dermatomyositis. Dermatomyositis is a rare autoimmune condition that attacks muscle…
- FDA rejects Osteal Therapeutics' combo therapy for joint-implant infectionsThe U.S. Food and Drug Administration rejected Osteal Therapeutics' lead combination therapy late last month. The agency cited concerns that prevented approval of the product intended to treat infe…